MedPath

浙江视方极医药科技有限公司

Ownership
-
Established
2021-02-03
Employees
-
Market Cap
-
Website
www.nbsfyy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

7

NMPA:7

Drug Approvals

Tobramycin Eye Drops

Product Name
妥布霉素滴眼液
Approval Number
国药准字H20253643
Approval Date
Mar 18, 2025
NMPA

Tobramycin Eye Drops

Product Name
妥布霉素滴眼液
Approval Number
国药准字H20253197
Approval Date
Jan 14, 2025
NMPA

Azelastine Hydrochloride Eye Drops

Product Name
盐酸氮䓬斯汀滴眼液
Approval Number
国药准字H20253094
Approval Date
Jan 8, 2025
NMPA

Azelastine Hydrochloride Eye Drops

Product Name
盐酸氮䓬斯汀滴眼液
Approval Number
国药准字H20253098
Approval Date
Jan 8, 2025
NMPA

Sodium Hyaluronate Eye Drops

Product Name
玻璃酸钠滴眼液
Approval Number
国药准字H20244804
Approval Date
Sep 3, 2024
NMPA

Calcium Dobesilate Tablets

Product Name
羟苯磺酸钙片
Approval Number
国药准字H20243543
Approval Date
Apr 17, 2024
NMPA

Metronidazole Tablets

Product Name
甲硝唑片
Approval Number
国药准字H64020013
Approval Date
Nov 14, 2019
NMPA

Clinical Trials

No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath